Our findings provide insights into apoptotic resistance mechanisms and investigate the combination of direct BAX activation and BCL-XL inhibition as a novel therapeutic strategy that can broadly overcome apoptotic resistance in cancer. This evidence concerns the gene BCL2L1 and cancer.